COVID-19 Records

Gates Package — page 1326

of 1375 pages

← p.1325 p.1327 → · this page in the original PDF · package

EXAMPLES OF PREVIOUS WORK IN THESE AREAS CAPABILITIES CONCEIVE CREATE CARRY THROUGH * 85+ investments across the Accelerators * Multiple companies launched after * Syndicates: Multiple leveraged funding portfolio from 2016-2022 receiving grants from the Accelerator partnerships across both commercial and government entities 'Sample Partners Select Examples . . G55 university * Government incentives: BMGF York. Ub NOVARTIS @ ensoma experience starting GAVI we most Gene therapy Se Ibi Oster: Raise $70M in Series A th NovarRTIS Seattle Children's lo Hospital ° Uni every chilis we Gene-based cure for sickle cell disease Ody ge NIR & Gifs FRED HUTCH ~ Significant 1:1 leveraged funding te CURES START HERETM Parte een A Engineering B cells . & = Raised $52M in Series A Collaboration on gene-based cures THERAPEUTICS for HIV and sickle cell disease EMORY Levers Cw $100M ou) funding Engineering B cells Org development for vaccine distribution +) And many more Raised $50M and $73M in $5.8B in grant funding from BMGF Series A funding committed to date Gf Not for distribution

This is our OCR of the page, with running headers and footers removed. The Committee's PDF is authoritative; quote from it. Machine-readable, including the uncleaned text: /api/page/gates/1326

Records on this page

RecordDateTypePages
gates:exh:00613 attachment 1326